|
|
Article: Genentech announces clinical trials testing TNKase (Tenecteplase) with leading anti-thrombotics for treatment of heart attack; Four studies pair clot-buster with varying combinations of adjunctive agents to seek improvements for heart attack patients.
- Article from:
- M2 Presswire
- Article date:
- March 15, 2000
CopyrightCOPYRIGHT 2000 Normans Media Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-15 March 2000-GENENTECH: Genentech announces clinical trials testing TNKase (Tenecteplase) with leading anti-thrombotics for treatment of heart attack; Four studies pair clot-buster with varying combinations of adjunctive agents to seek improvements for heart attack patients (C)1994-2000 M2 COMMUNICATIONS LTD
RDATE:13032000
SOUTH SAN FRANCISCO, Calif. -- Genentech, Inc. (NYSE: DNA) today announced plans to collaborate with other major pharmaceutical manufacturers to test the new, single-bolus thrombolytic, TNKase (Tenecteplase), in combination with various leading anti-thrombotic agents in the treatment of acute myocardial infarction (AMI), ...